The present invention provides novel human antibodies that specifically bind to CD123 as well as novel human antibodies that specifically bind to FLT3. The present invention further relates to complementary pairs of CyCAT® halfbody molecules encompassing the novel FLT3 and CD123 specific antibodies of the invention and their use in redirecting T- cell mediated killing of FLT3 and CD123 co-expressing leukemia cancer cells, via on-cell formation of T-cell engaging trispecific antibodies. The present disclosure also provides measures for optimizing the producibility of halfbody molecules as well as the safety profile of CyCAT directed therapies.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
The present invention provides anti-GM-CSF antibodies for use in the treatment of rheumatoid arthritis. Anti-GM-CSF antibodies, in particular MOR103, are administered to patients suffering from rheumatoid arthritis at dosages that are beneficial in a clinical setting.
C07K 16/24 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
A61K 31/519 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
A61K 39/00 - Medicinal preparations containing antigens or antibodies
A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
The present invention provides novel antibodies or antibody fragments specifically binding to human C5aR. In particular, it relates to antibodies or antibody fragments that have combined beneficial properties and are therefore useful for the treatment of inflammatory or autoimmune diseases or cancer.
Applicant discloses an anti-idiotypic antibody to MOR202. which when fused to human albumin. shifted the antibody in IFE thus mitigating any potential interference of MOR202 with the M-protein clinical assessment.
C07K 16/30 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
The present disclosure provides novel human antibodies that specifically bind to the TCR beta constant region 2 (TRBC2) with high affinity and selectivity.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
A61K 47/68 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
The present invention relates to polypeptides that are conformational constrained in an antiparallel, helix-turn-helix arrangement and which specifically bind to IL-13Rα2 but not to IL-13Rα1 and compete with IL-13 for binding to IL-13Rα2. The invention further relates to fusion proteins and pharmaceutical compositions comprising said polypeptides and to their use for diagnostic and therapeutic purposes.
The present disclosure relates to the treatment of anti-PLA2R-positive membranous nephropathy. The anti-CD38 antibody, MOR202, is efficacious when administered to patients at certain dosage regimens.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
A61K 31/138 - Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
A61K 31/167 - Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen atom of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
A61K 31/573 - Compounds containing cyclopenta[a]hydrophenanthrene ring systemsDerivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
A61K 39/00 - Medicinal preparations containing antigens or antibodies
A61P 13/12 - Drugs for disorders of the urinary system of the kidneys
A61P 37/06 - Immunosuppressants, e.g. drugs for graft rejection
8.
GENERATION AND PROFILING OF FULLY HUMAN THERAPEUTIC ANTIBODIES SPECIFIC FOR HUMAN CD38
The present invention provides novel antibodies and methods for using recombinant antigen-binding regions and antibodies and functional fragments containing such antigen-binding regions that are specific for CD38, which plays an integral role in various disorders or conditions. These methods take advantage of newly discovered antibodies and surprising properties of such antibodies, such as the ability to bind CD38 of minipig origin and the ability to induce, by cross-linking, specific killing of cells that express CD38. These antibodies as well as the novel methods for using those antibodies can be used to treat, for example, hematological malignancies such as multiple myeloma.
C07K 16/30 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
C07K 16/40 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against enzymes
9.
ANTI-CD38 ANTIBODIES FOR USE IN THE TREATMENT OF ANTIBODY-MEDIATED TRANSPLANT REJECTION
The present invention relates to the use of the anti-CD38 antibody felzartamab in the prophylaxis and/or treatment of antibody-mediated rejection (ABMR) of transplants. In accordance with the present invention, felzartamab is effective in the treatment of antibody-mediated renal allograft rejection.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
The present invention relates to the use of an anti-CD38 antibody or antibody fragment in the prophylaxis and/or treatment of diseases directly caused by immune complex deposits. In accordance with the present invention, an anti-CD38 antibody is effective in the treatment of IgA nephropathy (IgAN).
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
A61P 13/12 - Drugs for disorders of the urinary system of the kidneys
A61P 37/06 - Immunosuppressants, e.g. drugs for graft rejection
11.
COMPLEX-SPECIFIC ANTIBODIES AND ANTIBODY FRAGMENTS AND ITS USE
The present invention provides antibodies and fragments thereof that specifically detect the complex of a specific cognate antigen-binding moiety, in particular antibodies, and its antigen. The antibodies of the present disclosure do not bind either said cognate antigen binding moiety or said antigen alone and this can be used e.g. to directly detect antigen-bound antigen-binding moieties. Further disclosed are methods for production and use of said antibodies and antibody fragments.
C07K 16/42 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against immunoglobulins (anti-idiotypic antibodies)
C07K 16/24 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
G01N 33/68 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving proteins, peptides or amino acids
12.
THERAPY COMPRISING ANTI-CD19 ANTIBODY AND EZH2 MODULATORS
The present disclosure provides methods, pharmaceutical compositions, and kits for treating cancer in patients in need thereof. The methods comprise administering to a patient in need a EZH2 modulator, such as Compound I, or a pharmaceutically acceptable salt thereof, in combination with one or more anti-CD19 antibodies. Also provided are medicaments for use in treating cancer.
The present invention provides novel antibodies or antibody fragments specifically binding to human C5aR. In particular, it relates to antibodies or antibody fragments that have combined beneficial properties and are therefore useful for the treatment of inflammatory or autoimmune diseases or cancer.
Combination therapies comprising a SIRPaFc fusion protein and an anti-CD19 agent are provided. The combination therapies can optionally further include an E3 ubiquitin ligase modulator.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
The present invention provides affinity optimized and deimmunized human antibodies that specifically bind to CD3. The present disclosure also provides bispecific antibodies comprising the optimized human antibodies e.g. for activating of T cells. The invention further relates to methods of generating the human antibodies and methods of using them in the treatment of diseases.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
17.
CLINICAL ASSESSMENT OF M-PROTEIN RESPONSE IN MULTIPLE MYELOMA
Applicant discloses an anti-idiotypic antibody to MOR202, which when fused to human albumin, shifted the antibody in IFE thus mitigating any potential interference of MOR202 with the M-protein clinical assessment.
C07K 16/30 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
C07K 16/42 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against immunoglobulins (anti-idiotypic antibodies)
G01N 33/574 - ImmunoassayBiospecific binding assayMaterials therefor for cancer
The present disclosure provides anti-CD19 antibodies for use in the treatment of various cancers. The anti-CD19 antibody is administered to cancer patients in a specific dose or dosing regimen.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
The present invention relates to an in vitro method to reduce, prevent or abolish interference of a therapeutic anti-CD38 antibody in serological assay systems.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
C07K 16/42 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against immunoglobulins (anti-idiotypic antibodies)
G01N 33/543 - ImmunoassayBiospecific binding assayMaterials therefor with an insoluble carrier for immobilising immunochemicals
The present disclosure provides methods, pharmaceutical compositions, and kits for treating cancer in patients in need thereof. The methods comprise administering to a patient in need a small ubiquitin-like modifier (SUMO) activating enzyme (SAE) inhibitor, such as [(1R,2S,4R)-4-{[5-({4-[(1R)-7-chloro-1,2,3,4-tetrahydroisoquinolin-1-yl]-5-methyl-2-thienyl}carbonyl)pyrimidin-4-yl]amino}-2-hydroxy-cyclopentyl]methyl sulfamate (Compound I-263a) or a pharmaceutically acceptable salt, in combination with one or more anti-CD19 antibodies. Also provided are medicaments for use in treating cancer.
A61K 31/34 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
A61P 35/02 - Antineoplastic agents specific for leukemia
The present disclosure provides combinations or sets of two antigen binding molecule, in particular asymmetric combinations of such antigen binding molecules. Each of the two antigen binding molecules is composed of a targeting moiety with specificity for a tumor associated antigen fused to either the VL or VH domain of an antibody Fv domain specific for CD3. Once the two antigen binding molecules bind to their target antigen on the surface of a cell, the complementary VL and VH domain are capable to associate with each other thereby reconstituting the functional CD3 specific Fv domain and non-covalently dimerizing the two antigen binding molecules. The thus on-cell formed trispecific heterodimeric antibody molecule is capable of engaging and stimulating cytotoxic T-cells for tumor cell destruction.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
The present disclosure provides combinations or sets of two antigen binding molecule, in particular asymmetric combinations of such antigen binding molecules. Each of the two antigen binding molecules is composed of a targeting moiety with specificity for a tumor associated antigen fused to either the VL or VH domain of an antibody Fv domain specific for CD3. Once the two antigen binding molecules bind to their target antigen on the surface of a cell, the complementary VL and VH domain are capable to associate with each other thereby reconstituting the functional CD3 specific Fv domain and non-covalently dimerizing the two antigen binding molecules. The thus on-cell formed trispecific heterodimeric antibody molecule is capable of engaging and stimulating cytotoxic T-cells for tumor cell destruction.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
The present disclosure relates to the treatment of anti-PLA2R-positive membranous nephropathy. The anti-CD38 antibody, MOR202, is efficacious when administered to patients at certain dosage regimens.
A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
A61P 13/12 - Drugs for disorders of the urinary system of the kidneys
A61P 37/06 - Immunosuppressants, e.g. drugs for graft rejection
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
24.
TREATMENT OF ANTI-PLA2R AUTOANTIBODY-MEDIATED MEMBRANOUS NEPHROPATHY
The present disclosure relates to the treatment of anti-PLA2R-positive membranous nephropathy. The anti-CD38 antibody, MOR202, is efficacious when administered to patients at certain dosage regimens.
A61P 13/12 - Drugs for disorders of the urinary system of the kidneys
A61P 37/06 - Immunosuppressants, e.g. drugs for graft rejection
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
25.
METHOD TO INCREASE ANTIBODY YIELD DURING ION EXCHANGE CHROMATOGRAPHY
The present invention relates to a method for increasing antibody yield during antibody purification from a sample by ion exchange chromatography in flow-through mode by pre-conditioning the sample with Tris without the use of NaCl to adjust the conductivity.
C07K 16/24 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
The present invention relates to an improved method for peak fractionation and eluate collection during chromatography for purification of a human therapeutic antibody.
C07K 16/24 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
27.
ANTI-CD38 ANTIBODIES FOR USE IN THE TREATMENT OF ANTIBODY-MEDIATED TRANSPLANT REJECTION
The present invention relates to the use of the anti-CD38 antibody felzartamab in the prophylaxis and/or treatment of antibody-mediated rejection (ABMR) of transplants. In accordance with the present invention, felzartamab is effective in the treatment of antibody-mediated renal allograft rejection.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
A61P 37/06 - Immunosuppressants, e.g. drugs for graft rejection
28.
ANTI-CD38 ANTIBODIES FOR USE IN THE TREATMENT OF ANTIBODY-MEDIATED TRANSPLANT REJECTION
The present invention relates to the use of the anti-CD38 antibody felzartamab in the prophylaxis and/or treatment of antibody-mediated rejection (ABMR) of transplants. In accordance with the present invention, felzartamab is effective in the treatment of antibody-mediated renal allograft rejection.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
A61P 37/06 - Immunosuppressants, e.g. drugs for graft rejection
A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
01 - Chemical and biological materials for industrial, scientific and agricultural use
05 - Pharmaceutical, veterinary and sanitary products
42 - Scientific, technological and industrial services, research and design
Goods & Services
Reagents for scientific and medical research for use in the
research and production of small molecule pharmaceuticals;
active chemical ingredients for use in the manufacture of
pharmaceuticals, biopharmaceuticals, vaccines, and finished
drug products. Pharmaceutical preparations for the treatment of diseases
that involve dysregulation of epigenetic pathways;
pharmaceutical preparations for epigenetic modulators as
therapeutics; pharmaceuticals comprising small molecules;
small molecule compounds for medical use and drug delivery;
small molecule pharmaceuticals for the treatment of diseases
and conditions; pharmaceuticals and pharmaceutical
preparations for human use for the treatment and prevention
of diseases and disorders; antibodies sold as a component
ingredient of pharmaceuticals; antibodies for use in the
manufacture of active ingredients of pharmaceuticals and
vaccines; diagnostic preparations for medical purposes;
biological substances for human medical diagnostics and
analysis; clinical medical reagents; biological preparations
for medical purposes; pharmaceutical and veterinary
preparations, agents and substances. Research and development of pharmaceutical preparations,
medicines and vaccines; providing medical and scientific
research information; conducting clinical trials; scientific
and technological services and research and design services.
The present invention relates to the use of an anti-CD38 antibody or antibody fragment in the prophylaxis and/or treatment of diseases directly caused by immune complex deposits. In accordance with the present invention, an anti-CD38 antibody is effective in the treatment of IgA nephropathy (IgAN).
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
The present invention relates to the use of an anti-CD38 antibody or antibody fragment in the prophylaxis and/or treatment of diseases directly caused by immune complex deposits. In accordance with the present invention, an anti-CD38 antibody is effective in the treatment of IgA nephropathy (IgAN).
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
The present disclosure is directed to a therapeutic combination of an anti-CD19 antibody and R-CHOP or an anti-CD19 antibody, lenalidomide, and R-CHOP for use in the treatment of diffuse large B cell lymphoma. The present disclosure is also directed to a therapeutic combination of an anti-CD19 antibody, lenalidomide, and rituximab for use in the treatment of non-Hodgkin lymphoma, chronic lymphocytic leukemia, or acute lymphoblastic leukemia.
A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
A61K 31/454 - Non-condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
A61K 31/475 - QuinolinesIsoquinolines having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine
A61K 31/573 - Compounds containing cyclopenta[a]hydrophenanthrene ring systemsDerivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
A61K 31/675 - Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
A61K 31/704 - Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin, digitoxin
A61P 35/02 - Antineoplastic agents specific for leukemia
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
The present disclosure is directed to a therapeutic combination of an anti-CD19 antibody and R-CHOP or an anti-CD19 antibody, lenalidomide, and R-CHOP for use in the treatment of diffuse large B cell lymphoma. The present disclosure is also directed to a therapeutic combination of an anti-CD19 antibody, lenalidomide, and rituximab for use in the treatment of non-Hodgkin lymphoma, chronic lymphocytic leukemia, or acute lymphoblastic leukemia.
A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
A61P 35/02 - Antineoplastic agents specific for leukemia
A61K 31/454 - Non-condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
A61K 31/475 - QuinolinesIsoquinolines having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine
A61K 31/573 - Compounds containing cyclopenta[a]hydrophenanthrene ring systemsDerivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
A61K 31/675 - Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
A61K 31/704 - Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin, digitoxin
34.
ANTI-CD38 ANTIBODIES AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF AUTOANTIBODY-MEDIATED AUTOIMMUNE DISEASE
The present invention relates to the use of an antibody or antibody fragment specific for CD38 in the prophylaxis and/or treatment of autoantibody-mediated autoimmune disease. In accordance with the present invention, an anti-CD38 antibody is effective in the treatment of anti-PLA2R positive membranous glomerulonephropathy.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
A61P 37/06 - Immunosuppressants, e.g. drugs for graft rejection
35.
FAB Molecules with a Rodent Hinge Region and a Non-Rodent CH1 Region
The disclosure relates to novel Fab molecules comprising a modified heavy chain constant region. The modified constant region prevents the recognition of the Fab molecules by anti-Fab antibodies present in a host's serum. The disclosure further relates to methods of generating such modified Fab molecules for biological, diagnostic, pharmaceutical and other uses.
The present disclosure relates to formulations of a pharmaceutically active antigen binding protein, such as a monoclonal antibody. In particular, the present disclosure relates to a stable lyophilized pharmaceutical formulation of an anti-CD38 antibody, a reconstituted liquid formulation of such lyophilized formulation, and to methods of making and using such lyophilized and reconstituted formulations.
A61K 9/19 - Particulate form, e.g. powders lyophilised
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
37.
NOVEL HUMAN ANTIBODIES BINDING TO HUMAN CD3 EPSILON
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
C07K 16/32 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products from oncogenes
38.
NOVEL HUMAN ANTIBODIES BINDING TO HUMAN CD3 EPSILON
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
C07K 16/32 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products from oncogenes
Provided are compositions and therapies for treating cancer, by targeting both the C5aR and the PD-1/PD-L1 proteins in the patient. It is demonstrated herein that such combination treatments, when administered at suitable doses, achieve synergistic results.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
01 - Chemical and biological materials for industrial, scientific and agricultural use
05 - Pharmaceutical, veterinary and sanitary products
42 - Scientific, technological and industrial services, research and design
Goods & Services
Reagents for scientific and medical research for use in the research and production of small molecule pharmaceuticals; active chemical ingredients for use in the manufacture of pharmaceuticals, biopharmaceuticals, vaccines, and finished drug products; antibodies sold as a component ingredient of pharmaceuticals; antibodies for use in the manufacture of active ingredients of pharmaceuticals and vaccines. Pharmaceutical preparations for the treatment of diseases that involve dysregulation of epigenetic pathways; pharmaceutical preparations for epigenetic modulators as therapeutics; pharmaceuticals comprising small molecules; small molecule compounds for medical use and drug delivery; small molecule pharmaceuticals for the treatment of diseases and conditions; pharmaceuticals and pharmaceutical preparations for human use for the treatment and prevention of diseases and disorders; diagnostic preparations for medical purposes; biological substances for human medical diagnostics and analysis; clinical medical reagents; biological preparations for medical purposes; pharmaceutical and veterinary preparations, agents and substances. Research and development of pharmaceutical preparations, medicines and vaccines; providing medical and scientific research information; conducting clinical trials; scientific and technological services and research and design services.
Novel antigen-binding molecules are provided, with the ability to target different antigens with different valency, e.g. one antigen monovalently and another antigen bivalently.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
The present disclosure is directed to a combination therapy comprising an antibody or antibody fragment specific for CD19 and a polypeptide that blocks the SIRP?-CD47 innate immune checkpoint for use in the treatment of cancer, in particular hematological cancer such as leukemia or lymphoma.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
A61P 35/02 - Antineoplastic agents specific for leukemia
43.
ANTI-TUMOR COMBINATION THERAPY COMPRISING ANTI-CD19 ANTIBODY AND POLYPEPTIDES BLOCKING THE SIRPΑ-CD47 INNATE IMMUNE CHECKPOINT
The present disclosure is directed to a combination therapy comprising an antibody or antibody fragment specific for CD19 and a polypeptide that blocks the SIRPα-CD47 innate immune checkpoint for use in the treatment of cancer, in particular hematological cancer such as leukemia or lymphoma.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
01 - Chemical and biological materials for industrial, scientific and agricultural use
05 - Pharmaceutical, veterinary and sanitary products
42 - Scientific, technological and industrial services, research and design
Goods & Services
antibodies for use in the manufacture of active ingredients of pharmaceuticals and vaccines; Biological and biotechnological products used in industry and science, namely, antibodies and fragments of antibodies for use in the manufacture of pharmaceutical preparations; Biological preparations, namely, antibodies and fragments of antibodies for clinical or medical laboratory use and not for use in connection with pesticides for agricultural and horticultural use; biological preparations, namely, antibodies and fragments of antibodies for diagnostic use other than medical use auxiliary agents, carriers and substances for pharmaceutical preparations in the nature of antibodies sold as component ingredients of pharmaceuticals for the treatment of metabolic disorders, infectious diseases, cancer, inflammatory diseases, Alzheimer's, sepsis, and restenosis Scientific, biological, pharmaceutical and medical research and development services in the field of antibodies not for use in connection with pesticides for agricultural and horticultural use; laboratory research in the field of analytical chemistry, biochemistry, medicinal chemistry, drug development, biotechnology, microbiology and molecular biology not for use in connection with pesticides for agricultural and horticultural use; chemical, biochemical and biotechnological analysis and research services not for use in connection with pesticides for agricultural and horticultural use
01 - Chemical and biological materials for industrial, scientific and agricultural use
05 - Pharmaceutical, veterinary and sanitary products
42 - Scientific, technological and industrial services, research and design
Goods & Services
Biological and biotechnological products used in industry and science; Biological preparations for laboratories, for diagnostics, and for analysis and environmental analysis; antibodies for use in the manufacture of active ingredients of pharmaceuticals and vaccines. Antibodies and fragments of antibodies; auxiliary agents, carriers and substances for pharmaceutical preparations in the nature of antibodies sold as component ingredients of pharmaceuticals. Scientific, biological, pharmaceutical and medical research and services in the field of antibodies; laboratory research in the field of analytical chemistry, biochemistry, medicinal chemistry, drug development, biotechnology, microbiology and molecular biology; chemical, biochemical and biotechnological analysis and services..
01 - Chemical and biological materials for industrial, scientific and agricultural use
05 - Pharmaceutical, veterinary and sanitary products
42 - Scientific, technological and industrial services, research and design
Goods & Services
reagents for scientific and medical research for use in the research and production of small molecule pharmaceuticals; active pharmaceutical ingredients, namely, antibodies, proteins and small molecules for use in the manufacture of pharmaceuticals, biopharmaceuticals, vaccines, and finished drug products; antibodies for use in the manufacture of active ingredients of pharmaceuticals and vaccines pharmaceutical preparations for the treatment of diseases that involve dysregulation of epigenetic pathways; pharmaceutical preparations for epigenetic modulators as therapeutics; pharmaceuticals comprising small molecules for the treatment and prevention of metabolic disorders, infectious diseases, cancer, inflammatory diseases, Alzheimer's, sepsis, and restenosis; small molecule compounds for use as drug delivery agents in pharmaceuticals; small molecule compounds being pharmaceuticals for the treatment and prevention of diseases and disorders, namely, metabolic disorders, infectious diseases, cancer, inflammatory diseases, Alzheimer's, sepsis, and restenosis in humans; small molecule pharmaceuticals for the treatment of diseases and conditions, namely, metabolic disorders, infectious diseases, cancer, inflammatory diseases, Alzheimer's, sepsis, and restenosis; Pharmaceuticals and pharmaceutical preparations for human use for the treatment and prevention of diseases and disorders, namely, metabolic disorders, infectious diseases, cancer, inflammatory diseases, Alzheimer's, sepsis, and restenosis; antibodies sold as a component ingredient of pharmaceuticals for the treatment of metabolic disorders, infectious diseases, cancer, inflammatory diseases, Alzheimer's, sepsis, and restenosis; diagnostic preparations for medical purposes; biological substances for human medical diagnostics and analysis for the treatment of metabolic disorders, infectious diseases, cancer, inflammatory diseases, Alzheimer's, sepsis, and restenosis; Clinical medical reagents; Biological preparations for medical purposes, namely, for the treatment of metabolic disorders, infectious diseases, cancer, inflammatory diseases, Alzheimer's, sepsis, and restenosis; pharmaceutical and veterinary preparations, agents and substances for the treatment of metabolic disorders, infectious diseases, cancer, inflammatory diseases, Alzheimer's, sepsis, and restenosis Pharmaceutical research and development of pharmaceutical preparations, medicines and vaccines; providing medical and scientific research information; Scientific research in the nature of conducting clinical trials for others; scientific and technological services, namely, scientific research, analysis, and testing services in the fields of analytical chemistry, biochemistry, medicinal chemistry, drug development, biotechnology, microbiology and molecular biology; research and design services, namely, research and development in the field of antibodies and clinical research in connection with the treatment and prevention of metabolic disorders, infectious diseases, cancer, inflammatory diseases, Alzheimer's, sepsis, and restenosis
47.
Generation and profiling of fully human HuCAL gold-derived therapeutic antibodies specific for human CD38
The present invention provides novel antibodies and methods for using recombinant antigen-binding regions and antibodies and functional fragments containing such antigen-binding regions that are specific for CD38, which plays an integral role in various disorders or conditions. These methods take advantage of newly discovered antibodies and surprising properties of such antibodies, such as the ability to bind CD38 of minipig origin and the ability to induce, by cross-linking, specific killing of cells that express CD38. These antibodies as well as the novel methods for using those antibodies can be used to treat, for example, hematological malignancies such as multiple myeloma.
C07K 16/30 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
C07K 16/40 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against enzymes
The present disclosure provides antibodies or antibody fragments specific for GPVI. In particular, it relates to antibodies or antibody fragments that have combined beneficial properties and are therefore useful for the treatment or prophylaxis of GPVI related disorders or conditions, such as for example thrombotic or vascular disorders.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
The present invention relates to an improved method for peak fractionation and eluate collection during chromatography for purification of a human therapeutic antibody.
The present invention relates to an improved method for peak fractionation and eluate collection during chromatography for purification of a human therapeutic antibody.
The present invention relates to a method for increasing antibody yield during antibody purification from a sample by ion exchange chromatography in flow-through mode by pre-conditioning the sample with Tris without the use of NaCl to adjust the conductivity.
C07K 16/24 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
G01N 30/96 - Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography using ion-exchange
B01D 15/36 - Selective adsorption, e.g. chromatography characterised by the separation mechanism involving ionic interaction, e.g. ion-exchange, ion-pair, ion-suppression or ion-exclusion
B01D 15/38 - Selective adsorption, e.g. chromatography characterised by the separation mechanism involving specific interaction not covered by one or more of groups , e.g. affinity, ligand exchange or chiral chromatography
52.
METHOD TO INCREASE ANTIBODY YIELD DURING ION EXCHANGE CHROMATOGRAPHY
The present invention relates to a method for increasing antibody yield during antibody purification from a sample by ion exchange chromatography in flow-through mode by pre-conditioning the sample with Tris without the use of NaCl to adjust the conductivity.
C07K 16/00 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies
B01D 15/36 - Selective adsorption, e.g. chromatography characterised by the separation mechanism involving ionic interaction, e.g. ion-exchange, ion-pair, ion-suppression or ion-exclusion
B01D 15/38 - Selective adsorption, e.g. chromatography characterised by the separation mechanism involving specific interaction not covered by one or more of groups , e.g. affinity, ligand exchange or chiral chromatography
C07K 16/24 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
G01N 30/96 - Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography using ion-exchange
53.
ANTI-TUMOR COMBINATION THERAPY COMPRISING ANTI-CD19 ANTIBODY AND GAMMA DELTA T-CELLS
The present disclosure is directed to a combination therapy comprising an anti-CD19 antibody or antibody fragment thereof and gamma delta T-cells (Υσ T-cells) for use in the treatment of leukemia or lymphoma.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
A61K 35/17 - LymphocytesB-cellsT-cellsNatural killer cellsInterferon-activated or cytokine-activated lymphocytes
A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
A61P 35/02 - Antineoplastic agents specific for leukemia
A61K 39/00 - Medicinal preparations containing antigens or antibodies
48 Abstract The present invention relates to therapeutic compositions and methods for sequential treatment of cancer in human patients using therapeutic agents that bind to human CD1g.
A61K 39/42 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum viral
C07K 14/00 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
A61P 35/02 - Antineoplastic agents specific for leukemia
A61K 39/00 - Medicinal preparations containing antigens or antibodies
55.
ANTI-TUMOR COMBINATION THERAPY COMPRISING ANTI-CD19 ANTIBODY AND GAMMA DELTA T-CELLS
The present disclosure is directed to a combination therapy comprising an anti-CD19 antibody or antibody fragment thereof and gamma delta T-cells (?s T-cells) for use in the treatment of leukemia or lymphoma.
A61P 35/02 - Antineoplastic agents specific for leukemia
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
48 Abstract The present invention relates to therapeutic compositions and methods for sequential treatment of cancer in human patients using therapeutic agents that bind to human CD1g.
A61P 35/02 - Antineoplastic agents specific for leukemia
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
The present disclosure is directed to a therapeutic combination of an anti-CD19 antibody and lenalidomide for use in the treatment of hematological cancer patients. Furthermore, the present disclosure concerns extending the overall survival and/or the progression free survival in patients having specific types of hematological cancer.
A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
A61K 31/454 - Non-condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
The present invention provides anti-GM-CSF antibodies for use in the treatment of rheumatoid arthritis. Anti-GM-CSF antibodies, in particular MOR103, are administered to patients suffering from rheumatoid arthritis at dosages that are beneficial in a clinical setting.
C07K 16/24 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
A61K 31/519 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
59.
ANTI-CD19 THERAPY IN COMBINATION WITH LENALIDOMIDE FOR THE TREATMENT OF LEUKEMIA OR LYMPHOMA
The present disclosure is directed to a therapeutic combination of an anti-CD19 antibody and lenalidomide for use in the treatment of hematological cancer patients. Furthermore, the present disclosure concerns extending the overall survival and/or the progression free survival in patients having specific types of hematological cancer.
A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
A61K 31/454 - Non-condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
A61K 9/19 - Particulate form, e.g. powders lyophilised
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
The present invention relates to antibodies or fragments thereof binding to human WT1/HLA. In particular, the present invention relates to antibodies or fragments thereof that have combined improved and/or beneficial properties, and are therefore suited for clinical development.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
C07K 16/18 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans
C07K 14/47 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans from vertebrates from mammals
G01N 33/68 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving proteins, peptides or amino acids
The invention relates to novel libraries of linear and cyclic peptides, and methods of generating and screening such libraries for biological, pharmaceutical and other uses.
The present disclosure provides humanized antibodies that specifically bind to CD3 with an optimized affinity and induce T cell-mediated killing of tumour related target antigen high expressing cells with high potency but have limited killing activity on target antigen low expressing cells. The present disclosure also provides bispecific antibodies comprising a first antigen-binding domain that specifically binds to human CD3 with optimized affinity and a second antigen-binding molecule that specifically binds a tumor-related antigen. The disclosure further relates to methods of generating such humanized antibodies and bispecific antibodies for biological, diagnostic, pharmaceutical and other uses.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
C07K 16/32 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products from oncogenes
63.
ANTI-CD19 THERAPY IN PATIENTS HAVING A LIMITED NUMBER OF NK CELLS
The present disclosure provides characteristics and biomarkers in patients that benefit from treatment with anti-CD19 antibodies (MOR00208, XmAb5574). Furthermore, the present application relates to anti-CD19 antibodies for the treatment of leukemia or lymphoma in patients having a peripheral NK cell count at baseline of less or equal to 100 NK cells/μl
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
A61K 31/519 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
A61P 35/02 - Antineoplastic agents specific for leukemia
A61P 35/04 - Antineoplastic agents specific for metastasis
G01N 33/574 - ImmunoassayBiospecific binding assayMaterials therefor for cancer
G01N 33/50 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing
A61K 39/00 - Medicinal preparations containing antigens or antibodies
64.
ANTI-CD19 THERAPY IN PATIENTS HAVING A LIMITED NUMBER OF NK CELLS
The present disclosure provides characteristics and biomarkers in patients that benefit from treatment with anti-CD19 antibodies (MOR00208, XmAb5574). Furthermore, the present application relates to anti-CD19 antibodies for the treatment of leukemia or lymphoma in patients having a peripheral NK cell count at baseline of less or equal to 100 NK cells/µl
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
A61K 31/519 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
A61P 35/02 - Antineoplastic agents specific for leukemia
A61P 35/04 - Antineoplastic agents specific for metastasis
G01N 33/50 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing
G01N 33/574 - ImmunoassayBiospecific binding assayMaterials therefor for cancer
A61K 39/00 - Medicinal preparations containing antigens or antibodies
65.
ANTI-CD38 ANTIBODIES AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF AUTOANTIBODY-MEDIATED AUTOIMMUNE DISEASE
The present invention relates to the use of an antibody or antibody fragment specific for CD38 in the prophylaxis and/or treatment of autoantibody-mediated autoimmune disease. In accordance with the present invention, an anti-CD38 antibody is effective in the treatment of anti-PLA2R positive membranous glomerulonephropathy.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
A61K 39/00 - Medicinal preparations containing antigens or antibodies
A61P 13/12 - Drugs for disorders of the urinary system of the kidneys
66.
ANTI-CD38 ANTIBODIES AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF AUTOANTIBODY-MEDIATED AUTOIMMUNE DISEASE
The present invention relates to the use of an antibody or antibody fragment specific for CD38 in the prophylaxis and/or treatment of autoantibody-mediated autoimmune disease. In accordance with the present invention, an anti-CD38 antibody is effective in the treatment of anti-PLA2R positive membranous glomerulonephropathy.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
A61K 39/00 - Medicinal preparations containing antigens or antibodies
A61P 13/12 - Drugs for disorders of the urinary system of the kidneys
The present invention provides novel antibodies or antibody fragments specifically binding to human C5aR. In particular, it relates to antibodies or antibody fragments that have combined beneficial properties and are therefore useful for the treatment of inflammatory or autoimmune diseases or cancer.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
The present invention provides novel antibodies or antibody fragments specifically binding to human C5aR. In particular, it relates to antibodies or antibody fragments that have combined beneficial properties and are therefore useful for the treatment of inflammatory or autoimmune diseases or cancer.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
The invention relates to novel polypeptide libraries that are conformationally constrained in an anti-parallel, helix-turn-helix arrangement. The invention further relates to methods of generating and screening such libraries for biological, pharmaceutical and other uses.
C40B 40/10 - Libraries containing peptides or polypeptides, or derivatives thereof
C12N 15/10 - Processes for the isolation, preparation or purification of DNA or RNA
C40B 40/02 - Libraries contained in or displayed by microorganisms, e.g. bacteria or animal cellsLibraries contained in or displayed by vectors, e.g. plasmidsLibraries containing only microorganisms or vectors
The present invention provides antibodies or antibody fragments binding to human IL-17C. In particular, it relates to antibodies or antibody fragments that have combined beneficial properties and are therefore useful for the treatment of humans having, for example, atopic dermatitis or psoriasis.
C07K 16/24 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
A61K 39/00 - Medicinal preparations containing antigens or antibodies
C12N 15/62 - DNA sequences coding for fusion proteins
C12N 15/63 - Introduction of foreign genetic material using vectorsVectorsUse of hosts thereforRegulation of expression
A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
The present disclosure relates to formulations of a pharmaceutically active antigen binding protein, such as a monoclonal antibody. In particular, the present disclosure relates to a stable lyophilized pharmaceutical formulation of an anti-CD38 antibody, a reconstituted liquid formulation of such lyophilized formulation, and to methods of making and using such lyophilized and reconstituted formulations.
The present disclosure relates to formulations of a pharmaceutically active antigen binding protein, such as a monoclonal antibody. In particular, the present disclosure relates to a stable lyophilized pharmaceutical formulation of an anti-CD38 antibody, a reconstituted liquid formulation of such lyophilized formulation, and to methods of making and using such lyophilized and reconstituted formulations.
Novel antigen-binding molecules are provided, with the ability to target different antigens with different valency, e.g. one antigen monovalently and another antigen bivalently.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
C07K 16/32 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products from oncogenes
Novel antigen-binding molecules are provided, with the ability to target different antigens with different valency, e.g. one antigen monovalently and another antigen bivalently.
C07K 16/32 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products from oncogenes
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
Provided is a pharmaceutical combination comprising an antibody specific for CD19 and a natural killer cell, and a treatment method using the same. Such a pharmaceutical combination is capable of exhibiting synergistic therapeutic effects on a malignant tumor of B-cell origin such as non-Hodgkin's lymphoma, chronic lymphocytic leukemia, and/or acute lymphoblastic leukemia.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
76.
PHARMACEUTICAL COMBINATIONS FOR TREATING TUMOR COMPRISING ANTI-CD19 ANTIBODY AND NATURAL KILLER CELL
GREEN CROSS LAB CELL CORPORATION (Republic of Korea)
MORPHOSYS AG (Germany)
Inventor
Her, Jung Hyun
Jung, Mi Young
Gwon, Su Hyun
Lim, Ho Yong
Cho, Sung Yoo
Won, Sung Yong
Hwang, Yu Kyeong
Jan, Endell
Rainer, Boxhammer
Abstract
Provided is a pharmaceutical combination comprising an antibody specific for CD19 and a natural killer cell, and a treatment method using the same. Such a pharmaceutical combination is capable of exhibiting synergistic therapeutic effects on a malignant tumor of B-cell origin such as non-Hodgkin's lymphoma, chronic lymphocytic leukemia, and/or acute lymphoblastic leukemia.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
A61K 39/00 - Medicinal preparations containing antigens or antibodies
The present disclosure relates to the treatment of multiple myeloma. Monoclonal antibody MOR202 is efficacious when administered to patient at certain dosage regimens.
A61K 39/00 - Medicinal preparations containing antigens or antibodies
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
A61K 9/00 - Medicinal preparations characterised by special physical form
A61K 31/573 - Compounds containing cyclopenta[a]hydrophenanthrene ring systemsDerivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
The present invention provides recombinant antigen-binding regions, antibodies and functional fragments thereof that are specific for GM-CSF, which plays an integral role in various disorders or conditions. These antibodies, accordingly, can be used to treat, for example, inflammatory diseases such as rheumatoid arthritis. Antibodies of the invention also can be used in the diagnostics field, as well as for further investigating the role of GM-CSF in the progression of various disorders. The invention also provides nucleic acid sequences encoding the foregoing antibodies, vectors containing the same, pharmaceutical compositions and kits with instructions for use.
C12N 15/63 - Introduction of foreign genetic material using vectorsVectorsUse of hosts thereforRegulation of expression
C12N 15/64 - General methods for preparing the vector, for introducing it into the cell or for selecting the vector-containing host
C07K 16/24 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
A61K 39/00 - Medicinal preparations containing antigens or antibodies
The present disclosure describes high concentration liquid formulations of a pharmaceutically active antigen binding protein, for example a monoclonal antibody. Such formulations comprise, in addition to the antigen binding protein, at least 80mM of a buffering agent and at least 80mM of a stabilizer. In addition, the present disclosure is related to pharmaceutical formulations of an anti-IL-17C antibody and provides methods of making and methods of using such formulations.
C07K 16/24 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
A61K 39/00 - Medicinal preparations containing antigens or antibodies
A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
The present disclosure describes high concentration liquid formulations of a pharmaceutically active antigen binding protein, for example a monoclonal antibody. Such formulations comprise, in addition to the antigen binding protein, at least 80mM of a buffering agent and at least 80mM of a stabilizer. In addition, the present disclosure is related to pharmaceutical formulations of an anti-IL-17C antibody and provides methods of making and methods of using such formulations.
C07K 16/24 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
A61K 39/00 - Medicinal preparations containing antigens or antibodies
The present disclosure provides antibodies or antibody fragments specific for GPVI. In particular, it relates to antibodies or antibody fragments that have combined beneficial properties and are therefore useful for the treatment or prophylaxis of GPVI related disorders or conditions, such as for example thrombotic or vascular disorders.
A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
A61P 9/10 - Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
The present disclosure provides antibodies or antibody fragments specific for GPVI. In particular, it relates to antibodies or antibody fragments that have combined beneficial properties and are therefore useful for the treatment or prophylaxis of GPVI related disorders or conditions, such as for example thrombotic or vascular disorders.
A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
A61P 9/10 - Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
83.
Fab molecules with a rodent hinge region and a non-rodent CH1 region
The disclosure relates to novel Fab molecules comprising a modified heavy chain constant region. The modified constant region prevents the recognition of the Fab molecules by anti-Fab antibodies present in a host's serum. The disclosure further relates to methods of generating such modified Fab molecules for biological, diagnostic, pharmaceutical and other uses.
01 - Chemical and biological materials for industrial, scientific and agricultural use
05 - Pharmaceutical, veterinary and sanitary products
42 - Scientific, technological and industrial services, research and design
Goods & Services
Antibodies for scientific purposes and not for medical or veterinary use; Monoclonal antibodies for diagnostic use and not for medical or veterinary use; Biochemicals, namely, monoclonal antibodies for scientific or research use; Tagged antibodies for scientific and laboratory use; immunological antibodies not for medical use; Reagents for use in the development of monoclonal antibodies not for medical or veterinary purposes; biological and biotechnological products used in industry and science, namely, antibodies and fragments of antibodies for use in the manufacture of pharmaceutical preparations; biological preparations for laboratories, for diagnostics, and for analysis and environmental analysis, other than for medical or veterinary use Pharmaceuticals and pharmaceutical preparations for human and veterinary use for the treatment and prevention of metabolic disorders, infectious diseases, cancer, inflammatory diseases, autoimmune diseases, Alzheimer, sepsis, and restenosis; diagnostic antibodies for medical purposes; biological substances for human medical diagnostics and analysis for the treatment of metabolic disorders, infectious diseases, cancer, inflammatory diseases, autoimmune diseases, Alzheimer, sepsis, and restenosis; medical diagnostic reagents; clinical medical reagents; Biological preparations for medical and veterinary purposes for the treatment of metabolic disorders, infectious diseases, cancer, inflammatory diseases, autoimmune diseases, Alzheimer, sepsis, and restenosis; biological preparations for medical and veterinary purposes, namely, antibodies sold as a component ingredient of pharmaceuticals Research and development in the pharmaceutical and biotechnology fields; research and development of vaccines and medicines; scientific and technological services, namely, scientific research, analysis, and testing services in the fields of analytical chemistry, biochemistry, medicinal chemistry, drug development, biotechnology, microbiology and molecular biology; biological research; clinical research in connection with the treatment and prevention of metabolic disorders, infectious diseases, cancer, inflammatory diseases, autoimmune diseases, Alzheimer, sepsis, and restenosis; medical research; chemical and biochemical analysis services; laboratory research in the fields of analytical chemistry, biochemistry, medicinal chemistry, drug development, biotechnology, microbiology and molecular biology; providing medical and scientific research information in the field of pharmaceuticals and clinical trials; providing medical and scientific research information in the field of pharmaceuticals; research and development services in the field of antibodies
85.
ANTIBODIES AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF AUTOIMMUNE SKIN DISEASES
The present invention relates to the use of an antibody or antibody fragment specific for IL-17C in the prophylaxis and/or treatment of autoimmune skin diseases. In one embodiment, the antibody or antibody fragment specific for IL-17C comprises a HCDR1 region of amino acid sequence SEQ ID NO: 7, a HCDR2 region of amino acid sequence SEQ ID NO: 8, a HCDR3 region of amino acid sequence of SEQ ID NO: 9, a LCDR1 region of amino acid sequence SEQ ID NO: 13, a LCDR2 region of amino acid sequence of SEQ ID NO: 14 and a LCDR3 region of amino acid sequence SEQ ID NO: 15. In another embodiment, the antibody or antibody fragment specific for IL-17C comprises a variable heavy chain of SEQ ID NO: 17 and a variable light chain of SEQ ID NO: 16. In some embodiments the autoimmune skin disease is selected from pemphigus vulgaris, bullous pemphigoid, vasculitis, pyoderma gangrenosum and Sweet's disease.
C07K 16/24 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
The present invention provides antibodies or antibody fragments binding to human IL-17C. In particular, it relates to antibodies or antibody fragments that have combined beneficial properties and are therefore useful for the treatment of humans having, for example, atopic dermatitis or psoriasis.
C12N 15/62 - DNA sequences coding for fusion proteins
C12N 15/63 - Introduction of foreign genetic material using vectorsVectorsUse of hosts thereforRegulation of expression
C07K 16/24 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
A61K 39/00 - Medicinal preparations containing antigens or antibodies
A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
The present invention provides a pharmaceutical composition comprising an antibody for antibody fragment specific for IL-17C, in particular MOR106 for use in the treatment of atopic dermatitis and related conditions wherein the antibody is administered to patients at dosages that are beneficial in a clinical setting.
C07K 16/24 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
A61K 39/00 - Medicinal preparations containing antigens or antibodies
01 - Chemical and biological materials for industrial, scientific and agricultural use
05 - Pharmaceutical, veterinary and sanitary products
42 - Scientific, technological and industrial services, research and design
Goods & Services
Antibodies for scientific purposes, other than for medical or veterinary use; Monoclonal antibodies for diagnostic use [other than medical]; Biochemicals, namely, monoclonal antibodies scientific or research use; Tagged antibodies for scientific and laboratory use; immunological antibodies, other than for medical use; Reagents for use in the development of monoclonal antibodies [other than for medical or veterinary purposes]; biological and biotechnological products used in industry and science; biological preparations for laboratories, for diagnostics, and for analysis and environmental analysis. Pharmaceuticals and pharmaceutical preparations for human and veterinary use; antibodies; biological substances for human medical diagnostics and analysis; medical diagnostic reagents; clinical medical reagents; Biological preparations for medical and veterinary purposes. Research and development in the pharmaceutical and biotechnology fields; research and development of vaccines and medicines; scientific and technological services and research and design services; biological research, clinical research and medical research; chemical and biochemical analysis services; laboratory research in the fields of analytical chemistry, biochemistry, medicinal chemistry, drug development, biotechnology, microbiology and molecular biology; clinical research; providing medical and scientific research information in the field of pharmaceuticals; Research and development services in the field of antibodies.
89.
Generation and profiling of fully human HuCAL GOLD-derived therapeutic antibodies specific for human CD38
The present invention provides novel antibodies and methods for using recombinant antigen-binding regions and antibodies and functional fragments containing such antigen-binding regions that are specific for CD38, which plays an integral role in various disorders or conditions. These methods take advantage of newly discovered antibodies and surprising properties of such antibodies, such as the ability to bind CD38 of minipig origin and the ability to induce, by cross-linking, specific killing of cells that express CD38. These antibodies as well as the novel methods for using those antibodies can be used to treat, for example, hematological malignancies such as multiple myeloma.
C07K 16/30 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
C07K 16/40 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against enzymes
90.
Clinical assessment of M-protein response in multiple myeloma
Applicant discloses an anti-idiotypic antibody to MOR202, which when fused to human albumin, shifted the anti-body in IFE thus mitigating any potential interference of MOR202 with the M-protein clinical assessment.
C07K 16/42 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against immunoglobulins (anti-idiotypic antibodies)
C07K 16/18 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans
C07K 16/30 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
G01N 33/574 - ImmunoassayBiospecific binding assayMaterials therefor for cancer
C07K 16/24 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
A61K 39/00 - Medicinal preparations containing antigens or antibodies
The present disclosure provides humanized antibodies that specifically bind to CD3 with an optimized affinity and induce T cell-mediated killing of tumour related target antigen high expressing cells with high potency but have limited killing activity on target antigen low expressing cells. The present disclosure also provides bispecific antibodies comprising a first antigen-binding domain that specifically binds to human CD3 with optimized affinity and a second antigen-binding molecule that specifically binds a tumor-related antigen. The disclosure further relates to methods of generating such humanized antibodies and bispecific antibodies for biological, diagnostic, pharmaceutical and other uses.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
C07K 16/32 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products from oncogenes
The present disclosure relates to the treatment of multiple myeloma. Monoclonal antibody MOR202 is efficacious when administered to patient at certain dosage regimens.
A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
A61K 9/00 - Medicinal preparations characterised by special physical form
A61K 31/573 - Compounds containing cyclopenta[a]hydrophenanthrene ring systemsDerivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
The present invention provides synthetic canine antibody libraries, as well as polypeptides, nucleic acids, vectors, host cells and methods used in conjunction with these libraries. The present invention also provides antibodies isolated from such libraries.
The present disclosure provides anti-CD19 antibodies and venetoclax for use in the treatment of non-Hodgkin's lymphoma, chronic lymphocytic leukemia and/or small lymphocytic lymphoma. The anti-CD19 antibodies, in particular MOR00208, and venetoclax are administered to patients suffering non-Hodgkin's lymphoma (NHL), chronic lymphocytic leukemia (CLL) and/or small lymphocytic lymphoma (SLL) according to a specific treatment paradigm to mitigate therapy associated tumor lysis syndrome.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
96.
TREATMENT PARADIGM FOR AN ANTI-CD19 ANTIBODY AND VENETOCLAX COMBINATION TREATMENT
The present disclosure provides anti-CD19 antibodies and venetoclax for use in the treatment of non-Hodgkin's lymphoma, chronic lymphocytic leukemia and/or small lymphocytic lymphoma. The anti-CD19 antibodies, in particular MOR00208, and venetoclax are administered to patients suffering non-Hodgkin's lymphoma (NHL), chronic lymphocytic leukemia (CLL) and/or small lymphocytic lymphoma (SLL) according to a specific treatment paradigm to mitigate therapy associated tumor lysis syndrome.
A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
A61K 31/00 - Medicinal preparations containing organic active ingredients
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
The present invention provides antibodies or antibody fragments binding to human IL-17C. In particular, it relates to antibodies or antibody fragments that have combined beneficial properties and are therefore useful for the treatment of humans having, for example, atopic dermatitis or psoriasis.
C07K 16/24 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
C12N 15/62 - DNA sequences coding for fusion proteins
The present invention provides anti-GM-CSF antibodies for use in the treatment of rheumatoid arthritis. Anti-GM-CSF antibodies, in particular MOR103, are administered to patients suffering from rheumatoid arthritis at dosages that are beneficial in a clinical setting.
C07K 16/24 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
A61K 31/519 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
A61K 39/00 - Medicinal preparations containing antigens or antibodies
99.
Complex-specific antibodies and antibody fragments and its use
The present invention provides antibodies and fragments thereof that specifically detect the complex of a specific cognate antigen-binding moiety, in particular antibodies, and its antigen. The antibodies of the present disclosure do not bind either said cognate antigen binding moiety or said antigen alone and this can be used e.g. to directly detect antigen-bound antigen-binding moieties. Further disclosed are methods for production and use of said antibodies and antibody fragments.
C07K 16/42 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against immunoglobulins (anti-idiotypic antibodies)
C07K 16/24 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
G01N 33/68 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving proteins, peptides or amino acids
100.
FAB MOLECULES WITH A RODENT HINGE REGION AND A NON-RODENT CH1 REGION
The disclosure relates to novel Fab molecules comprising a modified heavy chain constant region. The modified constant region prevents the recognition of the Fab molecules by anti-Fab antibodies present in a host's serum. The disclosure further relates to methods of generating such modified Fab molecules for biological, diagnostic, pharmaceutical and other uses.
